<DOC>
	<DOCNO>NCT01588236</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety dose-response KYG0395 treatment primary dysmenorrhea .</brief_summary>
	<brief_title>Effect KYG0395 Primary Dysmenorrhea</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<criteria>Otherwise healthy female subject ( age 18 35 , BMI equal less 32 ) , primary dysmenorrhea least 3 consecutive menstrual cycle prior study ( prior start baseline cycle ) VAS score &gt; 70 maximum dysmenorrheic pain VAS score &gt; 40 average daily dysmenorrheic pain last menstrual cycle . Known suspected secondary dysmenorrhea due pelvic inflammation , endometriosis , uterine myoma , ovarian pathological change , pelvic disease . Pregnant try conceive study . Recent delivery , abortion , lactation within 3 menstrual cycle start treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>